3 Result: Eisai
LEQEMBI Breakthrough: FDA Approves Eisai and Biogen's Alzheimer's Therapy
July 07th, 2023
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) have received FDA approval for LEQEMBI (lecanemab-irmb), a groundbreaking treatment for Alzheimer's disease (AD), the most common type of dementia. LEQEMBI is the first approved therapy to demonstrate a . Read more
FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
July 06th, 2023
Action Follows Confirmatory Trial to Verify Clinical Benefit Silver Spring, MD / CRWE PRESS RELEASE / July 06, 2023 - Today, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult p. Read more
Biogen: FDA Panel Backs OK of Alzheimer's Drug; Disc Medicine: Upgraded, Promising Trial Data
June 10th, 2023
Eisai and Biogen's (Nasdaq: BIIB) Alzheimer's drug candidate, LEQEMBI (lecanemab-irmb), received unanimous support from FDA PCNS panel based on Phase 3 Clarity AD trial data. The committee acknowledged its clinical benefit, overall benefit-r. Read more
Want To Find Some News?
News By Industries
Recent Post
-
NJCP Football League Provides Development and Opportunity for Athletes Pursuing the Next Level
March 20th, 2026March 19th, 2026How High School Graduates Can Kickstart Their Football Career
March 18th, 2026
Member Login